Maryse Paquet
Overview
Explore the profile of Maryse Paquet including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
570
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sposato L, Cerasuolo J, Cipriano L, Fang J, Fridman S, Paquet M, et al.
Neurology
. 2018 Feb;
90(11):e924-e931.
PMID: 29444969
Objective: To compare the risk of 1-year ischemic stroke recurrence between atrial fibrillation (AF) diagnosed after stroke (AFDAS) and sinus rhythm (SR) and investigate whether underlying heart disease is as...
2.
Paquet M, Cerasuolo J, Thorburn V, Fridman S, Alsubaie R, Lopes R, et al.
J Stroke Cerebrovasc Dis
. 2017 Nov;
27(3):606-619.
PMID: 29141778
Background: It has been hypothesized that ischemic stroke can cause atrial fibrillation. By elucidating the mechanisms of neurogenically mediated paroxysmal atrial fibrillation, novel therapeutic strategies could be developed to prevent...
3.
Ritter-Makinson S, Paquet M, Bogenpohl J, Rodin R, Yun C, Weinman E, et al.
Neuroscience
. 2017 Apr;
353:58-75.
PMID: 28392297
The group II metabotropic glutamate receptors mGluR2 and mGluR3 are key modulators of glutamatergic neurotransmission. In order to identify novel Group II metabotropic glutamate receptor (mGluR)-interacting partners, we screened the...
4.
Gupta A, Paquet M
J Cutan Med Surg
. 2015 Mar;
19(3):260-73.
PMID: 25775640
Background: Onychomycosis has several clinical presentations and is caused by various infectious organisms. Objective: To provide guidance for selection of appropriate treatment. Methods: The literature on onychomycosis management was reviewed...
5.
Gupta A, Paquet M
J Dermatolog Treat
. 2014 Oct;
26(4):376-8.
PMID: 25329992
Cosmetic improvement in nail appearance is a great concern to patients with onychomycosis. Although oral and topical treatments for onychomycosis can potentially eradicate the infection, unsightly nails may remain despite...
6.
Evans M, Kalman D, Alvarez P, Paquet M, Guthrie N
Clin Cosmet Investig Dermatol
. 2014 Aug;
7:215-24.
PMID: 25143750
Purpose: Actinic keratosis lesions (AKs) have the potential to develop into squamous cell carcinoma (SCC) and thus therapies to prevent SCC development from AKs are warranted. The aim of this...
7.
Gupta A, Daigle D, Paquet M
J Am Podiatr Med Assoc
. 2014 Jul;
105(4):357-66.
PMID: 25032982
New therapies for onychomycosis continue to be developed, yet treatments are seldom directly compared in randomized controlled trials. The objective of this study was to compare the rates of mycological...
8.
Gupta A, Paquet M
J Am Podiatr Med Assoc
. 2014 Jun;
104(3):277-82.
PMID: 24901587
Placebo cure rates vary among randomized clinical trials for onychomycosis, but the factors influencing these cure rates have not been systematically investigated. The PubMed database and reference sections of relevant...
9.
Gupta A, Paquet M
J Cutan Med Surg
. 2014 May;
18(3):151-5.
PMID: 24800702
Background: Topical therapies for onychomycosis are associated with less adverse events than systemic therapies, but poor nail penetration limits their efficacy. Consequently, an efinaconazole 10% nail solution was developed. Objective:...
10.
Gupta A, Lane D, Paquet M
J Cutan Med Surg
. 2014 Mar;
18(2):79-90.
PMID: 24636433
Background: Extensive or recurrent tinea versicolor (TV) can be treated with systemic antifungal therapies, but no dosing regimens have been approved for this indication. Objective: To provide evidence-based recommendations for...